Eledon Reports Positive Long-Term Results for Tegoprubart in Kidney Transplantation
News related to:Eledon Pharmaceuticals, Inc · 2 min read
IRVINE, Calif., Sept. 22, 2026 /CourierPR/ -- Eledon Pharmaceuticals, Inc. has announced updated long-term data from its Phase 2 BESTOW clinical program evaluating tegoprubart in patients undergoing kidney transplantation. The results were presented at the International Congress of The Transplantation Society, which took place from September 20-23, 2026, in Sydney, Australia.
According to the study, patients treated with tegoprubart maintained statistically significantly higher kidney function as measured by mean estimated glomerular filtration rate (eGFR) through 24 months. Specifically, the mean eGFR was 71 mL/min/1.73 m² for tegoprubart-treated patients, compared to 58 mL/min/1.73 m² for those receiving tacrolimus, with an approximately 13 mL/min/1.73 m² advantage for tegoprubart at month 24. The data were extracted on August 31, 2026, and the results were significant at months 18, 21, and 24, as indicated by *p < 0.05.
Moreover, no cases of biopsy-proven acute rejection (BPAR) were reported in the tegoprubart arm beyond six months post-transplant, compared to seven cases in the tacrolimus arm. One new case of graft loss was observed in the tacrolimus arm.
Eledon Pharmaceuticals received Fast Track designation from the U.S. Food and Drug Administration (FDA) for tegoprubart in the prevention of rejection in kidney transplantation. The company plans to initiate its global Phase 3 trial, LEGACY, in the fourth quarter of 2026. The LEGACY trial is expected to enroll approximately 600 patients, with a primary endpoint of non-inferiority of tegoprubart versus tacrolimus on a composite efficacy failure endpoint at 12 months, defined as a combination of biopsy-proven acute rejection, graft loss, and death.
The BESTOW long-term extension study included 90 patients who had been followed through 18 months and 81 patients who had been followed through 24 months. The data for months 15 onward were collected from patients who completed treatment and enrolled in BESTOW EXTENSION.
The company's lead investigational product, tegoprubart, is an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target with broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention.